4.7 Article

Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 74, Issue 22, Pages 2758-2767

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.09.015

Keywords

sex differences; outcome differences over time; predictors of 30-day mortality; transfemoral aortic valve implantation

Funding

  1. Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation [CVON 2018-28, 2012-06]
  2. Dutch Federation of University Medical Centres
  3. Netherlands Organisation for Health Research and Development
  4. Royal Netherlands Academy of Sciences
  5. Edwards Lifesciences
  6. Abbott Laboratories
  7. AstraZeneca
  8. Bayer
  9. Beth Israel Deaconess
  10. Bristol-Myers Squibb
  11. Chiesi USA
  12. CSL Behring
  13. Eli Lilly/DSI
  14. Medtronic
  15. Novartis
  16. OrbusNeich
  17. PLC/Renal Guard

Ask authors/readers for more resources

BACKGROUND Transfemoral aortic valve replacement (TAVR) is a guideline-recommended treatment option for patients with severe aortic valve stenosis. Women and men present with different baseline characteristics, which may influence procedural outcomes. OBJECTIVES This study sought to evaluate differences between women and men undergoing transfemoral TAVR across the globe during the last decade. METHODS The CENTER (Cerebrovascular EveNts in patients undergoing TranscathetER aortic valve implantation with balloon-expandable valves versus self-expandable valves)-collaboration was a global patient level dataset of patients undergoing transfemoral TAVR (N = 12,381) from 2007 to 2018. In this retrospective analysis, the study examined differences in baseline patient characteristics, 30-day stroke and mortality, and in-hospital outcomes between female and male patients. The study also assessed for temporal changes in outcomes and predictors for mortality per sex. RESULTS We included 58% (n = 7,120) female and 42% (n = 5,261) male patients. Women had higher prevalence of hypertension and glomerular filtration rate <30 ml/min/1.73 m(2) but lower prevalence of all other traditional cardiovascular comorbidities. Both sexes had similar rates of 30-day stroke (2.3% vs. 2.5%; p = 0.53) and mortality (5.9% vs. 5.5%; p = 0.17). In contrast, women had a 50% higher risk of life-threatening or major bleeding (6.7% vs. 4.4%; p < 0.01). Over the study period, mortality rates decreased to a greater extent in men than in women (60% vs. 50% reduction; both p < 0.001), with no reductions in stroke rates over time. CONCLUSIONS In this global collaboration, women and men had similar rates of 30-day mortality and stroke. However, women had higher rates of procedural life-threatening or major bleeding after TAVR. Between 2007 and 2018, mortality rates decreased to a greater extent in men than in women. (C) 2019 Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available